GSA Capital Partners LLP Takes $47,000 Position in VYNE Therapeutics Inc. $VYNE

GSA Capital Partners LLP bought a new stake in VYNE Therapeutics Inc. (NASDAQ:VYNE) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 71,533 shares of the company’s stock, valued at approximately $47,000. GSA Capital Partners LLP owned 10.68% of VYNE Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of VYNE. ADAR1 Capital Management LLC boosted its stake in VYNE Therapeutics by 319.2% during the 1st quarter. ADAR1 Capital Management LLC now owns 1,063,899 shares of the company’s stock worth $636,000 after purchasing an additional 810,108 shares during the period. Rangeley Capital LLC increased its stake in VYNE Therapeutics by 18.1% in the first quarter. Rangeley Capital LLC now owns 118,064 shares of the company’s stock valued at $71,000 after purchasing an additional 18,064 shares during the period. KVP Capital Advisors LP purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at about $290,000. XTX Topco Ltd purchased a new stake in shares of VYNE Therapeutics in the fourth quarter valued at about $46,000. Finally, Anson Funds Management LP acquired a new stake in shares of VYNE Therapeutics during the fourth quarter worth about $739,000. Hedge funds and other institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Price Performance

Shares of NASDAQ VYNE opened at $28.32 on Wednesday. The stock has a fifty day moving average price of $31.94 and a 200 day moving average price of $31.47. VYNE Therapeutics Inc. has a 1-year low of $14.03 and a 1-year high of $79.75. The company has a market cap of $18.98 million, a PE ratio of -74.54 and a beta of 2.00.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($3.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($3.33). The firm had revenue of $0.10 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative net margin of 4,726.21% and a negative return on equity of 70.42%.

VYNE Therapeutics Announces Dividend

The company also recently announced a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were issued a $19.00 dividend.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of VYNE Therapeutics in a report on Monday, May 4th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, VYNE Therapeutics presently has a consensus rating of “Sell”.

VYNE Therapeutics Profile

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.